REstoring microvascular circulation with Diagnostic Ultrasound and Contrast agEnt (REDUCE): A multicentred, randomised, double blinded, controlled trial in patients presenting with ST elevation myocardial infarction.

niversity of Sydney0 个研究点目标入组 150 人开始时间: 2020年8月11日最近更新: 2024年2月27日

适应症

试验速览

暂无简介。

•Chest Pain with ST segment elevation >0.1 mV in two contiguous leads, or ST segment depression >0.2mV in two contiguous leads V1-V3 (consistent with a posterior STEMI)
•- Eligible for emergent PCI/antithrombotic/antiplatelet therapy.
•- Adequate apical and/or parasternal images by echocardiography.
•- No contraindications or hypersensitivities to ultrasound contrast agents.

•- Unable to provide written consent to participate in the trial
•- Chest pain lasting >6 hours
•- Cardiogenic shock
•- Fibrinolytic therapy prior to arrival in the emergency department
•- Life expectancy of less than six months from any other co-morbidity or terminally ill
•- Prior ST-segment elevation myocardial infarction (STEMI)
•- Known or suspected hypersensitivity to perflutren, the contrast agent used for the study
•- Known cardiomyopathy
•- Known severe valvular heart disease
•- Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin
•- Known large right to left intra-cardiac shunts
•- Pregnancy

发起方